Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01597050 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
A Phase 2 study of Lupus Erythematosus, Systemic and Lupus Erythematosus, Discoid, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 15
- Study locations
NCT01597050 is a Phase 2 study of Lupus Erythematosus, Systemic and Lupus Erythematosus, Discoid that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 54 participants, below the 201-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (73% lower). The trial reports 15 study locations across 12 states.
The verdict
NCT01597050, a Phase 2 study of Lupus Erythematosus, Systemic and Lupus Erythematosus, Discoid, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG R932333
Study Locations (15)
California
- Wallace Rheumatic Study Center - Los Angeles
- Stanford Dermatology - Redwood City
New York
- North Shore Long Island Health System - Lake Success
- Columbia University Medical Center - New York
Texas
- Metroplex Clinical Research Center - Dallas
- University of Texas Medical School at Houston - Houston
Indiana
- Memorial Medical Group Clinical Research Institute - South Bend
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Oklahoma
- Oklahoma Medical Research Foundation - Oklahoma City
Pennsylvania
- University of Pennsylvania-Dermatology Research Office - Philadelphia
Utah
- University of Utah Department of Dermatology - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01597050
The ClinicalTrials.gov registry entry for NCT01597050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (73% lower). The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01597050 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT01597050 about?
NCT01597050 is a clinical study titled "Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions". The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
What is the current status of trial NCT01597050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2012-08. Estimated completion is 2013-09.
What conditions does trial NCT01597050 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid.
What interventions are being tested in trial NCT01597050?
The interventions under investigation include: Placebo (DRUG), R932333 (DRUG).
Who is sponsoring clinical trial NCT01597050?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01597050 being conducted?
This trial has 15 study locations across California, Indiana, New York, North Carolina, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
RECRUITING · Phase 2
-
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
RECRUITING · Phase 2
-
Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 2
-
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
COMPLETED · Phase 2
-
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
COMPLETED · Phase 2
-
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
COMPLETED · Phase 2
Explore more on PlainTrial
Lupus Erythematosus, Systemic
All registered trials for this condition
Lupus Erythematosus, Discoid
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.